|
|
|
|
| Advertisement |
 |
|
|
| Advertisement |
NORD's Rare Diseases and Orphan Products Breakthrough Summit
is the most meaningful multi-stakeholder event – historically featuring over 20 speakers from the FDA, participation from over 80 patient organizations and the Pharma/Biotech industry's foremost experts in orphan product innovation, investment and commercialization.
The 2016 Summit is your opportunity to address the progress and innovations in rare disease diagnosis, treatment, engagement and access of orphan products.
 Learn more |
|
| Regulatory |
 |
|
New Challenge to IP Innovation |
For generic firms, Inter Partes Reviews (IPRs) are a cost-effective way to clear out FDA Orange Book-listed patents before or during litigation; for originator companies, they pose a threat to valuable patent portfolios. Steve Maebius reports
... /Read more/ |
|
|
| Advertisement |
Technology can't replace people- why Patient Support Programs need a personal approach
Live Webcast: Thursday, September 29 at 8:00 EDT
 Free registration |
|
| Advertisement |
Optimizing real-world evidence programs to generate value
Tailored approaches for emerging biopharma
Live Webinar: Wednesday, September 14 at 10:00am EDT
 Register now |
|
|
| Advertisement |
Breaking the Circle of Distrust with a Radical PLC Pricing Model
On Demand
 Learn more |
|
| Industry update |
| //ProclaRx (Columbus, OH) announced the appointment of Dinar Dhond to its Board of Directors.//BeiGene, Ltd. (Waltham, MA) appointed Amy C. Peterson, M.D. as Chief Medical Officer, Immuno-oncology.//AstraZeneca has agreed to sell its late-stage small-molecule antibiotics business to Pfizer.// |
| Advertisement |
Best Practices for Integrating Biomarkers
across the Drug Development Continuum
On Demand
 Learn more |
|
|
|
| |
|
